Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of “Moderate Buy” by Brokerages

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been given an average rating of “Moderate Buy” by the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $13.75.

A number of research analysts recently issued reports on VYGR shares. Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. HC Wainwright cut their price target on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, November 11th.

Voyager Therapeutics Stock Performance

NASDAQ VYGR opened at $3.39 on Friday. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $5.55. The stock has a market cap of $188.48 million, a PE ratio of -1.57 and a beta of 1.30. The firm has a 50-day moving average of $3.99 and a 200-day moving average of $4.09.

Insider Activity at Voyager Therapeutics

In related news, CEO Alfred Sandrock sold 12,192 shares of the stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $3.78, for a total transaction of $46,085.76. Following the transaction, the chief executive officer directly owned 509,989 shares of the company’s stock, valued at $1,927,758.42. This represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 20,286 shares of company stock worth $77,248. Company insiders own 6.39% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Privium Fund Management B.V. boosted its holdings in Voyager Therapeutics by 16.6% during the 2nd quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock worth $79,000 after acquiring an additional 3,596 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Voyager Therapeutics by 9.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 61,775 shares of the company’s stock valued at $249,000 after purchasing an additional 5,422 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Voyager Therapeutics by 1.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 303,133 shares of the company’s stock valued at $1,191,000 after purchasing an additional 5,560 shares in the last quarter. American Century Companies Inc. boosted its holdings in Voyager Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after purchasing an additional 6,748 shares during the last quarter. Finally, Jain Global LLC boosted its holdings in Voyager Therapeutics by 44.1% during the third quarter. Jain Global LLC now owns 28,104 shares of the company’s stock worth $131,000 after purchasing an additional 8,600 shares during the last quarter. 48.03% of the stock is owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.